Direct Evidence for Active Metalloproteinases Mediating Matrix Degradation in Interleukin 1-Stimulated Human Articular Cartilage
References (31)
- et al.
Modulation of human chondrocyte metabolism by recombinant human interferon gamma: In-vitro effects on basal and IL-1-stimulated roteinase production, cartilage degradation and DNA synthesis
Biochim. BiophYs. Acta
(1989) - et al.
Rabbit rocolla enase synthesized and secreted by a high-Yield mammalian expression vector requires stromelysin matrix metallo-Proteinase-3 for maximal activation
. Biol. Chem.
(1990) - et al.
Interleukin 1 preferentially stimulates the production of tissue-type Plasminogen activator by human articular chondrocYtes
Biochim. BiophYs. Acta
(1987) - et al.
Recombinant human interleukin-1 stimulates human articular cartilage to undergo resorption and human chondrocytes to produce both tissue- and urokinase-type plasminogen activator
Biochim. Biophys. Acta
(1988) - et al.
Proteoglycan degradation by a chondrocyte metalloproteinase
Effects of synthetic protease inhibitors. Biochem. Pharmacol.
(1987) - et al.
The degradation of type II collagen in rheumatoid arthritis: an immunoelectron microscopic study
Matrix
(1991) - et al.
Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue
Biochim. Biophys. Acta
(1986) - et al.
Regulation of the mammalian collagenases
Collagen Rel. Res.
(1984) - et al.
The complete primary structure of human matrix metalloproteinase-3
Identity with stromelysin. J. Biol. Chem.
(1988) - et al.
Synthesis of type II collagen is decreased in cartilage cultured with interleukin 1 while the rate of intracellular degradation remains unchanged
Collagen Rel. Res.
(1988)
Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage
J. Biol. Chem.
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
Arthritis Rheum.
Human articular cartilage secretes characteristic metal-dependent proteinases upon stimulation by mononuclear cell factor
J. Rheumatol.
The action of human articular cartilage metalloproteinase on proteoglycan and link protein
Similarities between in situ and in vitro degradation products. Biochem. J.
Protease inhibitors decrease rabbit cartilage degradation after meniscectomy
J. Ortho p. Res.
Cited by (94)
Unravelling the potential of nanocarriers to deliver Curcumin for the management of Rheumatoid Arthritis
2023, Journal of Drug Delivery Science and TechnologyDelivery of anti-inflammatory peptides from hollow PEGylated poly(NIPAM) nanoparticles reduces inflammation in an ex vivo osteoarthritis model
2017, Journal of Controlled ReleaseCitation Excerpt :Pathological persistent activation of immune cells such as macrophages causes sustained release of pro-inflammatory cytokines such as interleukin-1 (IL-1) [4,5], interleukin-6 (IL-6) [6–8], and tumor necrosis factor-alpha (TNF-α) [8] which can aggravate or accelerate damage to the surrounding tissues. The elevated levels of inflammatory cytokines result in upregulation of proteolytic enzymes that degrade key components of the extracellular matrix such as aggrecan and collagen [9,10], facilitating penetration of inflammatory factors deeper into the cartilage. Initial treatment of OA often includes orally administered anti-inflammatory compounds such as non-steroidal anti-inflammatory drugs (NSAIDs) or newer compounds that inhibit specific pro-inflammatory cytokines such as Enbrel or Humira (both targeting TNF-α [11]) and Kineret (targeting IL-1 [12]).
The role of proteases in pathologies of the synovial joint
2008, International Journal of Biochemistry and Cell BiologyInflammatory Basis of Spinal Pain
2007, Interventional Spine E-Book: An Algorithmic ApproachThe in vitro effects of dehydroepiandrosterone on human osteoarthritic chondrocytes
2003, Osteoarthritis and Cartilage
- 3
Present address: Rheumatology Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
- 4
Present address: Genetics Unit, Shriners Hospital, Montreal, Quebec, Canada.
- 5
Present address: St. Paul's Hospital, Vancouver, British Columbia, Canada.
- 6
Present address: Ciba Geigy, Summit, NJ, USA.
- 7
Dr. J. S. Mort, Joint Diseases Laboratory, Shriners Hospital for Crippled Children, 1529 Cedar Avenue, Montreal, Quebec, Canada H3G 1A6.